Formed in 2011 by Christopher Watt and Samuel Thangiah, Life Science Integrates (LSI) brings together Senior Leaders from across the Life Sciences, including industry, academia, government and regulators; providing them with unique opportunities to be part of the conversations that set out the industry’s challenges and identify effective strategies and solutions.
Our purpose is to find novel and engaging ways to bring people together; to discuss, debate and uncover the strategic solutions to their industry’s challenges by creating environments that challenge traditional concepts and enable constructive debate around disruptive innovations, business models and supply chains to ensure that today’s ideas and concepts will become the effective therapies and diagnostics of the future. Ultimately helping to ensure that the Life Science Industry delivers the best possible outcomes for patients and carers.
Life Science Integrates has enabled the conversations that have helped shape our industry today and will set the direction for the future.
Bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
Mark Egerton, Chief Executive Officer, Quotient Sciences, spoke to Lu Rahman about the company’s acquisition of Arcinova and what it means for the drug discovery sector.
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, today announced further positive interim results from its ongoing clinical study.
CatSci, a scientifically-led, commercially-minded and award-winning innovation partner for medicines development, is expanding its capabilities in material science, analytical science and preformulation studies to better serve its customers’ needs.
